These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 32317181)

  • 61. CDK12: cellular functions and therapeutic potential of versatile player in cancer.
    Pilarova K; Herudek J; Blazek D
    NAR Cancer; 2020 Mar; 2(1):zcaa003. PubMed ID: 34316683
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
    Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
    EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer.
    Lautert-Dutra W; M Melo C; Chaves LP; Crozier C; P Saggioro F; B Dos Reis R; Bayani J; Bonatto SL; Squire JA
    Mol Cytogenet; 2024 May; 17(1):11. PubMed ID: 38704603
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
    Vrábel D; Svoboda M; Navrátil J; Kohoutek J
    Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
    Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
    Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
    Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
    Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
    bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
    Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
    Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies.
    Frank S; Persse T; Coleman I; Bankhead A; Li D; De-Sarkar N; Wilson D; Rudoy D; Vashisth M; Galipeau P; Yang M; Hanratty B; Dumpit R; Morrissey C; Corey E; Montgomery RB; Haffner MC; Pritchard C; Vasioukhin V; Ha G; Nelson PS
    bioRxiv; 2024 Jul; ():. PubMed ID: 39071291
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
    Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
    Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
    Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
    Naidoo K; Wai PT; Maguire SL; Daley F; Haider S; Kriplani D; Campbell J; Mirza H; Grigoriadis A; Tutt A; Moseley PM; Abdel-Fatah TMA; Chan SYT; Madhusudan S; Rhaka EA; Ellis IO; Lord CJ; Yuan Y; Green AR; Natrajan R
    Mol Cancer Ther; 2018 Jan; 17(1):306-315. PubMed ID: 29133620
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome.
    Ashcraft KA; Johnson-Pais TL; Troyer DA; Hernandez J; Leach RJ
    Urol Oncol; 2020 Dec; 38(12):932.e1-932.e7. PubMed ID: 32665124
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
    Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
    JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
    Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
    Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
    Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.